CI
ALNY icon

Cowen Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cowen Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24,600
Closed -$3K – 327
2018
Q3 		$3K Buy
+24,600
New +$2.47M ﹤0.01% 483
2017
Q3 		– Sell
-10,700
Closed -$853K – 225
2017
Q2 		$853K Buy
10,700
+10,643
+18,672% +$680K 0.05% 181
2017
Q1 		$292K Sell
57
-22,443
-100% -$1.04M 0.01% 196
2016
Q4 		$843K Buy
22,500
+9,000
+67% +$377K 0.04% 155
2016
Q3 		$915K Buy
+13,500
New +$952K 0.05% 143
2016
Q2 		– Sell
-13,700
Closed -$860K – 209
2016
Q1 		$860K Buy
+13,700
New +$911K 0.03% 156

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Cowen Inc's ALNY Position: Q4 2017 in Review

Cowen Inc sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2017, closing a stake of 5,700 shares — an estimated $670K sold.

Cowen Inc first reported a position in ALNY in Q3 2015 and held it in 4 quarters. The position peaked at $670K in Q3 2017. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

  • Cowen Inc reported no remaining Alnylam Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Cowen Inc sold 5,700 Alnylam Pharmaceuticals shares in Q4 2017, an estimated $670K.
  • Cowen Inc first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Cowen Inc's Alnylam Pharmaceuticals position peaked at $670K in Q3 2017.
  • 282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on Cowen Inc's 13F filing for Q4 2017, filed 15 Feb 2018.